Tag

Ai Drug Discovery

All articles tagged with #ai drug discovery

business12 days ago•2 min saved

Lilly inks AI-driven oral drug deal with Insilico worth up to $2.75B

Eli Lilly and Insilico Medicine have agreed to a commercialization deal valued at up to $2.75 billion (including $115 million upfront) to develop, manufacture, and bring to market Insilico’s AI-discovered preclinical oral drug candidates, with milestones tied to regulatory and commercial success. The companies deny rumors of a full acquisition, and specific asset details aren’t disclosed, though a GLP-1 candidate has been licensed to an undisclosed partner.

via statnews.com|

#ai-drug-discovery #biobucks #business

business13 days ago•2 min saved

Lilly inks $2.75B deal to commercialize AI‑discovered drugs with Insilico

Eli Lilly agreed to a $2.75 billion deal to bring AI‑discovered drugs from Insilico Medicine to the global market, with $115 million upfront and remaining milestones plus royalties. Insilico has developed about 28 AI‑driven drug candidates, roughly half in clinical stages, and will join Lilly’s Gateway Labs; the collaboration—dating to a 2023 AI software license—aims to accelerate discovery across multiple disease areas as Lilly expands its AI‑driven R&D and China investment strategy.

via CNBC|

#ai-drug-discovery #business #eli-lilly

health6 months ago•5 min saved

AI-Driven Discovery of Targeted Antibiotics for Gut Bacteria and IBD

Researchers at MIT and McMaster University used AI, specifically DiffDock, to develop and understand a targeted antibiotic, enterololin, that treats gut bacteria linked to Crohn's disease with minimal impact on the microbiome, potentially revolutionizing treatment and reducing antimicrobial resistance.

via MIT News|

#ai-drug-discovery #antibiotics #crohns-disease

business7 months ago•4 min saved

Lilly Launches Free AI Platform for Biotech Drug Discovery

Eli Lilly has launched Lilly TuneLab, an AI/ML platform offering biotech companies access to proprietary drug discovery models trained on over $1 billion of Lilly's research data, aiming to accelerate innovation and support early-stage drug development through a privacy-preserving federated learning approach.

via Eli Lilly|

#ai-drug-discovery #biotechnology #business

health-and-technology9 months ago•2 min saved

Google DeepMind Prepares for First Human Trials of AI-Designed Drugs

Google DeepMind's affiliate, Isomorphic Labs, is preparing to begin human trials of AI-designed drugs, aiming to revolutionize drug development by increasing success rates and reducing costs, leveraging breakthroughs like AlphaFold for protein modeling.

via Fortune|

#ai-drug-discovery #alphafold #clinical-trials

healthtech2 years ago•2 min saved

"Isomorphic Labs' Lucrative Drug Discovery Deals with Novartis and Lilly"

Isomorphic Labs, a drug discovery spin-out of DeepMind, has partnered with Eli Lilly and Novartis to use AI for drug discovery, with deals totaling $3 billion. Isomorphic will receive upfront payments and potential milestone-based incentives. The company utilizes DeepMind's AlphaFold 2 AI technology to predict protein structures, aiding in drug design. While not perfect, AlphaFold has shown promise in designing potential drugs for diseases like liver cancer and is being applied to neglected diseases. Isomorphic is under pressure to turn a profit after recording a loss in 2021.

via TechCrunch|

#ai-drug-discovery #alphafold-2 #eli-lilly

technology-and-business2 years ago•8 min saved

"ByteDance Expands into Biosciences with Foray into Drug Discovery"

ByteDance, the Chinese company behind TikTok, is expanding into the science and healthcare sectors, recruiting U.S. experts in computational biology, quantum chemistry, and drug design. The company's AI for Drug Design and AI for Science teams are working on projects that could revolutionize drug discovery using AI. While ByteDance's objectives remain unclear, the data from TikTok could potentially be leveraged for these initiatives, raising concerns about data privacy and the use of social media information in scientific research. This move may also be part of ByteDance's strategy to diversify its portfolio and improve its image amidst scrutiny and potential bans in the U.S.

via Forbes|

#ai-drug-discovery #bytedance #data-privacy

healthcare2 years ago•0 min saved

Merck KGaA partners with BenevolentAI and Exscientia for AI-driven drug discovery

Merck KGaA has entered into separate AI drug discovery partnerships with BenevolentAI and Exscientia, focusing on targets in oncology, neurology, and immunology. Exscientia will receive $20 million upfront for each of the three projects, with a total deal value of $674 million across all milestones. BenevolentAI will receive a low double-digit million dollar payment upfront, potentially worth $594 million, and both companies may receive tiered royalties on future sales.

via Endpoints News|

#ai-drug-discovery #benevolentai #exscientia

biotechnology2 years ago•0 min saved

Genesis Therapeutics Secures $200M Series B Funding for AI Drug Discovery and Clinical Testing

Genesis Therapeutics has raised $200 million in Series B financing, co-led by Andreessen Horowitz and an anonymous life science investor. The startup, which utilizes artificial intelligence to design small molecule drugs, plans to use the funds to further develop its AI technologies, expand its pipeline, and advance its first computer-generated drugs into clinical studies.

via Endpoints News|

#ai-drug-discovery #andreessen-horowitz #biotechnology